ITEM VIEW

Splenectomy in haematology - A 5-year single centre experience

dc.contributor.authorWood L.
dc.contributor.authorBaker P.M.
dc.contributor.authorMartindale A.
dc.contributor.authorJacobs P.
dc.date.accessioned2011-05-15T16:16:31Z
dc.date.available2011-05-15T16:16:31Z
dc.date.issued2005
dc.identifier.citationHematology
dc.identifier.citation10
dc.identifier.citation6
dc.identifier.issn10245332
dc.identifier.other10.1080/10245330500183418
dc.identifier.urihttp://hdl.handle.net/10019.1/13817
dc.description.abstractObjective: To define indications and outcome in haematologic cases undergoing splenectomy. Study design: A retrospective review of clinica l records from consecutive patients having open or laparoscopic removal of the spleen in an academic centre in the private sector. Endpoints were survival, operating time, spleen size, histopathology, requirements for blood or related products complications and average costs. Results: In the total group (n = 69) there were two deaths. Referrals were for immune thrombocytopaenia (41%), acquired haemolytic anaemia (10%), myeloproliferative syndrome (9%), acute or chronic leukaemia (19%), lymphoma (13%) and a miscellaneous group (8%), comprising cholelithiasis, aplasia or as a diagnostic procedure for otherwise unexplained splenomegaly. An open midline approach was predicated by spleens greater than twice normal size and a history of any bleeding disorder. Here the mean operating time was 83-min (range 40-295) whereas for laparoscopy this was 251-min (range 181-272). Summary: Careful stratification between the two options facilitated optimum haemostasis and consequently reduced requirement for packed red cells and platelets. Neither underlying pathology nor the choice of treatment influenced morbidity or mortality. Overall local experience is consistent with published international standards of surgical practice. Outcome is directly proportional to the number of each procedure carried out by a single team, observance of consistent protocols for preoperative evaluation and standardized proactive management through the recovery period. © 2005 Taylor & Francis.
dc.subjectazathioprine
dc.subjectcyclophosphamide
dc.subjectimmunosuppressive agent
dc.subjectprednisone
dc.subjectvincristine
dc.subjectacquired hemolytic anemia
dc.subjectacute leukemia
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectaplasia
dc.subjectcholelithiasis
dc.subjectchronic leukemia
dc.subjectcontrolled study
dc.subjectdisease association
dc.subjectfemale
dc.subjecthealth care cost
dc.subjecthuman
dc.subjectlaparoscopy
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmyeloproliferative disorder
dc.subjectoperation duration
dc.subjectplasmapheresis
dc.subjectpriority journal
dc.subjectretrospective study
dc.subjectreview
dc.subjectsplenectomy
dc.subjectstatistical analysis
dc.subjectstatistical significance
dc.subjectsurgical mortality
dc.subjectsurvival rate
dc.subjectthrombocytopenia
dc.subjectthrombotic thrombocytopenic purpura
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnemia, Hemolytic
dc.subjectChild
dc.subjectHematologic Diseases
dc.subjectHumans
dc.subjectLeukemia, Myeloid, Chronic
dc.subjectLymphoma
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyeloproliferative Disorders
dc.subjectRetrospective Studies
dc.subjectSplenectomy
dc.subjectSplenomegaly
dc.subjectThrombocytopenia
dc.subjectTreatment Outcome
dc.titleSplenectomy in haematology - A 5-year single centre experience
dc.typeReview
dc.description.versionReview


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW